Supriya Lifescience Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹206 Cr +3% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
SL

Supriya Lifescience Ltd

Q3 FY26

Supriya Lifescience Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹206Cr
+10.8% YoY
+3% QoQ
Net profit
₹50Cr
+6.4% YoY
0% QoQ
Margin
35%
−1 pp YoY
−1 pp QoQ
Price₹805
Market cap₹7.4K Cr
P/E35.1

The short version

Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products.

From Supriya Lifescience Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond.
  • Expectation to achieve INR1,000 crores revenue milestone in FY27 supported by:
  • Scale-up of existing product basket in regulated markets.
  • Launch of 3 to 4 new products per year, with new products contributing around 10% of revenue in 2-3 years.
  • Commercial revenue from the newly commissioned Ambernath finished formulation facility starting Q4 FY26, with full impact in FY27.
  • Backward integration is increasing, currently at 74%, expected to rise to 80-82% soon.
  • Long-term aim includes healthy growth via new products, contract manufacturing, and CDMO pipeline.

2 more points from Supriya Lifescience Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility.
  • Remaining FY26 capex expected around INR 15 crores for maintenance and small projects like Riboflavin block and formulation plant needs.
  • Planned ground-breaking for Patalganga site utilities block in coming year with initial INR 40-50 crores investment.
  • Future plan includes setting up either an API or formulation facility at Patalganga targeted around FY29.
  • Ambernath facility capex estimated between INR 140-160 crores; commercial revenue expected from Q4 FY26, EBITDA positive around Q3 FY27.

2 more points from Supriya Lifescience Ltd's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has good visibility on the order book for Q4 FY26, confident of achieving the revenue targets.
  • For the ATS-8 product for FY27, they have identified annual consumption for end users, with many in the signing stage of volume commitments.
  • Large contracts for CDMO/CMO are under discussion, with term sheets being signed; announcements expected in coming quarters.

2 more points from Supriya Lifescience Ltd's call on order book

Create a free account to keep reading this call

Supriya Lifescience Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Supriya Lifescience Ltd Q3 FY26 results — key figures

Supriya Lifescience Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue206186+10.8%200+3%
Operating profit (EBITDA)7266+9.1%73-1.4%
Operating margin35%36%-1 pp36%-1 pp
Profit before tax6763+6.3%68-1.5%
Net profit (PAT)5047+6.4%500%
EPS (₹)6.175.81+6.2%6.27-1.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹206 Cr, net profit ₹29 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Supriya Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Supriya Lifescience Ltd Q3 FY26 results?

Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products.

What is Supriya Lifescience Ltd share price analysis?

Supriya Lifescience Ltd currently shows a neutral. The stock trades at a P/E of 35.1 with a market cap of ₹7,353 Cr. Investors should review the full earnings analysis for detailed insights.

Is Supriya Lifescience Ltd planning capital expenditure?

Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility.

Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.